Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies.
Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies.
复制标题
DOI：
10.1038/bjc.1998.658
复制
发表时间：
1998-11
影响因子：
8.8
通讯作者：
Hamdy, F C
中科院分区：
文献类型：
--
作者：
Autzen, P;Robson, C N;Bjartell, A;Malcolm, A J;Johnson, M I;Neal, D E;Hamdy, F C
前列腺腺癌通常转移到骨。与大多数其他骨骼继发性肿瘤不同，大多数骨骼前列腺转移瘤本质上是成骨细胞性的，而不是溶骨性的。几种已知刺激骨形成的生长因子在良性和恶性前列腺细胞中表达，但没有一种与骨硬化转移有关。骨形态发生蛋白（BMPs）在体内诱导异位骨形成。我们之前报道过BMP-6 mRNA和蛋白在大多数具有骨骼转移的原发性前列腺癌中表达，但很少在临床上器官局限的肿瘤中表达。本研究通过原位杂交检测了BMP-6 mRNA在匹配的前列腺原发性和继发性骨病变、前列腺腺癌和其他常见人类恶性肿瘤的分离骨转移灶中的表达。在13例前列腺癌骨转移病例中的11例以及3例原发性前列腺癌和匹配的骨转移病例中检测到BMP-6 mRNA。17例非前列腺恶性肿瘤的骨骼沉积物中有5例存在BMP-6的弱信号。BMP-6 mRNA似乎在前列腺腺癌中强烈表达，无论是原发性肿瘤还是骨转移。它也在其他人类癌症的骨骼转移中表达，尽管不太常见。我们的研究结果表明，BMP-6可能是骨骼转移的一个有吸引力的标志物和可能的介质，特别是在前列腺癌中。
Prostatic adenocarcinoma commonly metastasizes to bone. Unlike most other bony secondaries, the majority of skeletal prostatic metastases are osteoblastic rather than osteolytic in nature. Several growth factors which are known to stimulate bone formation are expressed in benign and malignant prostate cells, but none has been specifically linked to osteosclerotic metastases. Bone morphogenetic proteins (BMPs) induce ectopic bone formation in vivo. We have reported previously that BMP-6 mRNA and protein are expressed in the majority of primary prostatic carcinomas with established skeletal metastases but rarely in clinically organ-confined tumours. This study examines the expression of BMP-6 mRNA in matched prostatic primary and secondary bony lesions and in isolated skeletal metastases from prostatic adenocarcinomas, as well as other common human malignancies, by in situ hybridization. BMP-6 mRNA was detected in 11 out of 13 bone metastases from prostate carcinoma and in three paired samples of primary prostate carcinoma and matching skeletal metastasis. Weak signals for BMP-6 were also present in 5 out of 17 skeletal deposits from non-prostatic malignancies. BMP-6 mRNA appears to be strongly expressed in prostatic adenocarcinomas, both in the primary tumour and in bone metastases. It is also expressed, though less frequently, in skeletal metastases from other human carcinomas. Our findings suggest that BMP-6 may hold potential as an attractive marker and possible mediator of skeletal metastases, particularly in prostate carcinoma.